financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
Mar 4, 2024 11:01 PM

01:00 PM EST, 02/29/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target to $71 from $47 on a P/S of 7.5x, above its three-year average on good sales execution and a favorable deal pipeline, using our next-12-month sales estimate of $2.3B. We lift our FY 24 EPS view to $1.07 from $0.95 and FY 25's to $1.33 from $1.21. NTNX posted Q2 sales of $565.2M, above consensus by $14.8M, while non-GAAP EPS of $0.46 beat by $0.17. Revenue rose 16.2% Y/Y from solid Subscription revenue growth (+18% Y/Y) as ACV billings outperformed, up 23% Y/Y, from higher-than-anticipated renewals. We note NTNX's commentary around a continued uncertain macro environment, and longer average sales cycles, which likely impacted contract duration of 2.8 years in Q2, lower than Q1. However, these results reflect the firm's strong execution in securing and keeping pace with renewals and expansion deals, as well as maintaining healthy pricing levels in spite of these challenges. Its upbeat guidance and a higher mix of large deals in the pipeline further support our positive view of the business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Keeps Strong Sell Opinion On Shares Of The Chemours Company
Research Alert: CFRA Keeps Strong Sell Opinion On Shares Of The Chemours Company
May 26, 2025
02:25 AM EDT, 05/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target at $9, using a forward P/E of 5x our 2026 EPS view of $1.86 (cut by $0.17), below the three-year average of 6.5x on near-term...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings
Research Alert: CFRA Maintains Hold Opinion On Shares Of Arm Holdings
May 26, 2025
02:30 AM EDT, 05/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We reduce our 12-month target price to $115 from $130, based on a P/E of about 50x our CY 26 EPS estimate of $2.31, which is well above peers given...
Research Alert: CFRA Maintains Hold Opinion On Shares Of Borgwarner Inc.
Research Alert: CFRA Maintains Hold Opinion On Shares Of Borgwarner Inc.
May 26, 2025
03:10 AM EDT, 05/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month target of $32, based on a 2026 P/E of 7.0x and a justified discount to the stock's five-year average forward P/E of 11.1x. We lower our...
Research Alert: CFRA Keeps Hold Opinion On Adss Of Novo Nordisk
Research Alert: CFRA Keeps Hold Opinion On Adss Of Novo Nordisk
May 26, 2025
05:55 AM EDT, 05/08/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our EPADS estimates to DKK26.70 from DKK27.90 for 2025 and to DKK32.10 from DKK32.90 for 2026 in view of the guidance cut, while our target price of USD64...
Copyright 2023-2026 - www.financetom.com All Rights Reserved